KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

BACKGROUND: Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton’s tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may have benefit in patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Wang, Michael, Munoz, Javier, Goy, Andre, Locke, Frederick L., Jacobson, Caron A., Hill, Brian T., Timmerman, John M., Holmes, Houston, Jaglowski, Samantha, Flinn, Ian W., McSweeney, Peter A., Miklos, David B., Pagel, John M., Kersten, Marie José, Milpied, Noel, Fung, Henry, Topp, Max S., Houot, Roch, Beitinjaneh, Amer, Peng, Weimin, Zheng, Lianqing, Rossi, John M., Jain, Rajul K., Rao, Arati V., Reagan, Patrick M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7731441/
https://ncbi.nlm.nih.gov/pubmed/32242358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1914347
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados